nificant increase in exercise capacity (3.7 ml/kg/min (3.0-4.7)), along with improvements in insulin sensitivity (0.55 (0.43-1.2)), total adiponectin (780.9 μg/ml (262.1-1,497.1)) and leptin (-5.1 ng/ml (-14.5 to -3.3)). There were improvements in biomarkers of kidney disease very quality of life measures, but kidney function remained unchanged. Conclusion: Lifestyle modification is feasible in obese patients with CKD and produces weight loss that is related to improvements in exercise capacity, insulin resistance and adipokines. Whether lifestyle-induced weight loss and fitness can be sustained and whether it will mediate improvements in kidney function over time merits further investigation.
(eGFR) and hypertension with hyperinsulinemic-euglycemic clamp derived insulin sensitivity [3] . Data suggest that higher levels of insulin resistance are either independently associated with cardiovascular disease complications in CKD, or predict mortality in CKD when combined with unhealthy but modifiable lifestyles [4, 5] . Reduced physical activity levels and exercise capacity in CKD also contribute to disease progression and cardiovascular disease mortality [6] . Indeed, CKD patients usually manifest symptoms of exercise intolerance such as muscle weakness and fatigue and are less active, exhibiting muscle atrophy when compared to inactive normal subjects [7] [8] [9] .
In general, weight loss through exercise and diet (i.e. lifestyle modification) reduces adiposity, systemic blood pressure (BP) and blood glucose in obese adults by lowering inflammation and insulin resistance and by improving aerobic capacity [10] . Interestingly, targeting obesity induced vascular dysfunction and glucose intolerance in patients with CKD may also prove effective for kidney function. Thus, utilizing exercise and diet as a first-line therapy for reducing renal dysfunction risk is reasonable. Despite the magnitude of obesity and CKD in the general population, there are relatively few studies that have examined the impact of diet and exercise programs in the CKD population [11] [12] [13] [14] [15] . Furthermore, the reduced exercise tolerance previously observed in CKD populations raise concerns as to the feasibility of an exercise intervention program to promote clinically meaningful weight loss.
We hypothesized that lifestyle modification is feasible in obese individuals with CKD and will be associated with clinically meaningful weight loss. Moreover, we hypothesized that this weight loss would be related to improvements in exercise capacity (i.e. maximal oxygen consumption (VO 2max )), body composition, insulin resistance, adipokine profiles (i.e. high adiponectin and low leptin), inflammation and kidney function. Hence, we investigated the feasibility and effects of weight loss achieved during the first 12 weeks of a pilot lifestyle intervention in obese adults with CKD. In addition, we also studied the potential mechanisms related to obesity that might account for the beneficial effects of weight loss in CKD.
Methods

Subjects
Patients who had an eGFR <60 ml/min/1.73 m 2 , a body mass index (BMI) >30 and were being followed at the Cleveland Clinic Renal Clinic (identified using electronic medical record) were considered for inclusion. Demographic characteristics (age, gender and race), comorbidities (type 2 diabetes, hypertension, hyperlipidemia, etc.) and medication use were determined. Baseline comorbid conditions were identified using electronic medical record documentation (ICD-9 codes/medication). Subjects provided both verbal and written informed consent as approved by the Cleveland Clinic Foundation Institutional Review Board. Participants came to the Clinical Research Unit (CRU) for metabolic and body composition measures at baseline and, again, after 3 months into the program.
Exercise Training
All exercise training sessions were supervised by an exercise physiologist or research nurse and were conducted in the Exercise Physiology Laboratory at the Cleveland Clinic Foundation CRU. The primary mode of exercise training was walking on a treadmill. Exercise was prescribed at 65-85% of maximum heart rate (HR max ) for 45-60 min/session, and subjects were expected to exercise once per day for 5 days/week for 12 weeks. Initially, exercise was prescribed for 30-40 min/day during weeks 1-4, 40-50 min/day during weeks 5-8 and then 50-60 min/day during weeks 9-12. A typical exercise session began with 5-10 min of warm-up, 10 min of cycle ergometry, 30-40 min of treadmill walk/jog with an appropriate grade, 10 min of cycle ergometry and 5-10 min of cool down. Compliance with the training was carefully documented through regular attendance at the training sessions.
Diet Counseling
Participants were seen by a registered dietitian during their first visit. At baseline, a 3-day food diary was used to obtain details about participant's dietary habits. Resting energy expenditure was determined using indirect calorimetry after an overnight fast (Vmax Encore, Viasys Sensormedics, Yorba Linda, Calif., USA), and this resting energy expenditure was multiplied by an activity factor of 1.2 to estimate total daily energy requirements. Subjects were individually counseled on how to reduce their daily caloric intake by 500 kcal (50-60% carbohydrate, 25-30% fat and 15%, i.e. 0.8-1.0 g/kg/day of protein) throughout the intervention. Compliance with the diet was monitored weekly during visits to the CRU for the exercise program.
Body Composition
Anthropometric measures (height, weight and waist circumference) were measured by standard techniques, and BMI was calculated. Whole body fat mass (FM) and fat-free mass were measured by dual-energy X-ray absorptiometry (model iDXA; GE Healthcare -Lunar, Madison, Wis., USA).
Insulin Resistance, Inflammation and Adipokine Measures
A 75-g oral glucose tolerance test was performed after a 10-12 h of overnight fast. Anti-diabetic medication (e.g. insulin, metformin, etc.) was withheld for 24 h prior to testing to minimize the effects on glucose metabolism. Fasting blood samples were drawn to determine initial glucose, insulin, leptin and total/high molecular weight adiponectin concentrations. Following these baseline draws, a 75-g glucose drink was ingested within a 10-minute period, and blood samples were collected at 30, 60, 90, 120 and 180 min after ingestion to determine postprandial plasma glucose and insulin. Plasma glucose was determined immediately on the YSI 2300 STAT Plus analyzer (Yellow Springs, Ohio, USA). The remaining samples were stored at -80 ° C for subsequent analysis.
Plasma insulin was determined via radioimmunoassay (Millipore, Billerica, Mass., USA). Insulin resistance was determined from the homeostasis model assessment of insulin resistance (HOMA-IR) and the Matsuda index [16] . Fasting high sensitivity C-reactive protein, plasma leptin and total and high molecular weight adiponectin were analyzed via ELISA (Millipore, Billerica, Mass., USA). All blood samples were measured in duplicate, and each participant's pre-and post-intervention samples were batch-analyzed to minimize intra-subject variability.
Kidney Function Measures
Details of 125 I-sodium iothalamate GFR (iGFR) determination at the Cleveland Clinic have been previously described [17] . Briefly, patients received a water load before the test. 125 I-sodium iothalamate (25 Cu; Glofil; Questor Pharmaceuticals, Union City, Calif., USA) was injected subcutaneously without epinephrine. Baseline urine and blood samples were obtained. A voluntaryvoided urine sample was discarded, followed by one timed clearance urine collection. Blood samples were drawn before and after each urine collection. Isotope activity was determined by gamma counting of 0.5 ml of plasma or urine on the Packard Minaxi 5000 series counter (Perkin Elmer Life Sciences, Downers Grove, Ill., USA). The counts in each period were the average of the samples for each clearance period. The mean iGFR was calculated with and without standardizing to body surface area (1.73 m 2 ) using the Dubois and Dubois formula.
Cystatin C and β-2 Microglobulin
From fasting blood collections, cystatin C and β-2 microglobulin were analyzed as potentially novel biomarkers for renal function. Plasma cystatin C was measured using a particle enhanced immunoturbidimetric assay [18] . β-2 microglobulin was measured using an immunoturbidimetric assay (Roche). Both assays were run on the Roche Cobas c311 analyzer, a high throughput chemistry analyzer. Proteinuria measurements and 24-hour creatinine clearance were performed using standard methods at our institution.
Measurement of Exercise Tolerance and Quality of Life
VO 2max during an incremental treadmill test was used as the criterion to measure physical fitness. Three of the 4 following criteria were required to consider the test maximum: plateau in VO 2 (<150 ml/min), heart rate within 15 bpm of age-predicted HR max , volitional fatigue and/or a respiratory exchange ratio >1.0. Measurements of VO 2max were made at 4-week intervals to adjust exercise training intensity accordingly. Kidney Disease and Quality of Life-36 was administered before and after the 12 week intervention.
Statistical Analysis
We described patient characteristics and medication intake as n (%), and summarized continuous variables with medians and interquartile ranges (IQRs). The change in values (exercise capacity, kidney function measures, adipokines, insulin resistance and weight loss) from baseline to 12 weeks after the program was evaluated using the Wilcoxon signed-rank test. Spearman correlations were used to determine associations between the change in iGFR (adjusted and unadjusted) and the changes in metabolic markers (e.g. leptin, adiponectin and insulin resistance). Significance was accepted at p values <0.05. Data analyses were conducted using the Unix SAS version 9.2 (SAS Institute, Cary, N.C., USA), and graphs were created using R 3.0.1 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Subject Characteristics
Fifteen participants consented and underwent a screening treadmill exercise stress test. Twelve participants who had a negative test were enrolled, and 9 completed the 12-week intervention (one moved out of town, one developed transient atrial fibrillation that resolved and another with pre-existing back pain worsened leading to withdrawal from the program). Table 1 outlines the baseline characteristics of the study population (n = 9). In brief, median age was 57 years (IQR 51-63) with 77% being female and 33% whites. All included patients had hypertension and hyperlipidemia. The median BMI was 43. ( table 2 ) . Total adiponectin levels increased (change 780.9 μg/ml (262.1-1,497.1)) along with a significant decrease in plasma leptin (change -5.1 ng/ml (-14.5 to -3.3)) at 12 weeks ( fig. 1 ). Change in total adiponectin correlated with change in insulin resistance ( fig. 2 ) .
Exercise Capacity Improvement in exercise capacity was observed as early as 4 weeks into the program, and this improvement continued through 8-and 12-week time points ( fig. 3 ) . 
Renal Function
Kidney function measures did not change significantly after 12 weeks of lifestyle modification ( table 3 ) .
Quality of Life
After 12 weeks of intervention, there were significant changes in mental composite scores (median change 2.6 (0.49-11.1), p = 0.04), and there was a trend toward a decrease in kidney disease (median change 7.8 (0.00-16.3), p = 0.05), while there were no significant changes in the physical composite, burden of kidney disease or symptoms.
Discussion
In this short-term prospective study, lifestyle intervention was effective in achieving weight loss and improving body composition, physical fitness, insulin sensitivity, BP and adipokine profiles in obese subjects with CKD. Even though this was a select group of participants, compliance was higher and improvements noted were similar to what has been reported in the non-CKD population. In particular, the improvement in VO 2max was encouraging since 4 of our 9 patients were below 17.5 ml/kg/min at baseline, where the 3-year risk for mortality due to cardiovascular disease is elevated [19] . By week 8, all participants had achieved a VO 2max above this cutoff. This is significant given evidence of reduced exercise capacity in the CKD population, and overall cardiovascular disease risk reduction. Until the recent publications detailing positive benefits to CKD patients by exercise interventions, there has been a common perception that relatively vigorous exercise could not be tolerated by these patients. In contrast to other studies that examined less strenuous exercise interventions [14, 15, 20] , our data suggest that this is not the case. Indeed, these individuals with CKD were quite capable of achieving exercise levels equivalent to 60 min/day, 5 days/week, at ∼ 80% of HR max .
Our data demonstrate that improvements in metabolic health in CKD are achievable through diet and exercise interventions. As shown in obese insulin-resistant nondiabetic and type 2 diabetics without CKD [21, 22] , we demonstrated here that an exercise and diet intervention inducing approximately 6% fat loss effectively reduces insulin resistance in individuals with CKD. While stable isotope technology or use of arteriovenous sampling would be needed to determine the exact role of skeletal muscle and hepatic glucose production as a mechanism for improved glucose regulation in this study, we did observe significant improvements in both fasting and postprandial glucose concentrations. This suggests that hepatic glucose production and skeletal muscle insulin sensitivity may have been improved. Indeed, insulin sensitivity estimated by the Matsuda index, which is strongly linked to skeletal muscle glucose disposal, and HOMA-IR, a fasting measure of insulin resistance reflecting hepatic glucose output, showed significant improvements in our study population [16] . In addition, we observed significant correlations between insulin sensitivity and adiponectin, suggesting that increased adiponectin may be an important mechanism that confers protection against obesity-related inflammation and insulin resistance. Interestingly, the observed improvement in adiponectin reported herein is consistent with prior work by our group, suggesting that adiponectin is an important endocrine factor related to exercise and weight loss improvements in glucose regulation [23] . Taken together, since reduced multiorgan insulin sensitivity is a key risk factor for a future cardiovascular event in people with and without CKD, it seems reasonable to infer that systemic improvements in insulin action are likely to result in lower cardiovascular disease risk and reduction in future mortality [4] .
Another crucial aspect of the improvement in insulin resistance in this population is the reduction in circulating insulin. Hyperinsulinemia in obesity is associated with alterations in glomerular hemodynamics and can also cause cell proliferation and renal injury by promoting the expression of growth factors such as transforming growth factor (TGF)-β and the downregulation of matrix metalloproteinase-2, an enzyme responsible for matrix degradation [24, 25] . TGF-β has been shown to promote renal fibrosis, while hyperinsulinemia can increase TGF-β expression in proximal tubular cells, which may be related to extracellular matrix proliferation that is characteristic of diabetic nephropathy [26] . Our observations of reductions in fasting and post-prandial insulin concentrations suggest that improvements in insulin sensitivity are an important etiological factor in the development of CKD-related hypertension and heart disease. In fact, we noted improvements in diastolic BP and resting heart rate, which are known cardiovascular risk factors. Further studies are needed to understand how insulin contributes to the development of renal injury related to hypertension.
Although our intervention did not generate measurable improvements in biomarkers of kidney function, this was not entirely unexpected. We recently demonstrated that bariatric surgery, which produced rapid and robust improvements in insulin sensitivity, did not produce improvements in kidney function until 1 year post surgery [27] . These data indicate that while kidney function restoration is possible, it may require sustained long-term improvements in metabolic health to see measurable effects on kidney function. In fact, when taken together with our prior work [15] , reductions in body fat do not appear to be the primary determinant for improving kidney function. Nevertheless, we acknowledge that there is no consensus currently about the utility of various biomarkers to assess changes in kidney function following clinically meaningful weight loss. Thus, our data highlight the need for additional studies to identify the optimal lifestyle approach for managing kidney function and the need for larger studies with long-term follow-up to evaluate efficacy and durability of such an approach [28] .
Our study has some limitations that may affect our interpretation of results. We acknowledge that our sample size is modest. However, our study is unique in that these subjects were able to complete an intense aerobic exercise program (5 days/week) while most published studies in this population either had twice or thrice a week supervised intervention [14, 20] . In addition, the reasons for the 3 participants dropping out were unrelated to the intervention per se. Otherwise, adherence rates were comparable to the wider population. Perhaps more importantly for this subject population is the observation that non-dialysis-dependent CKD patients have poor quality of life including fatigue, inadequate sleep and depression [29] . In our study, we noted improvements in several quality of life parameters (effects of kidney disease and SF 36 mental composite), which suggests the potential psychological beneficial effects of lifestyle interventions in CKD. Next, our study may be subject to selection bias as patients who perceived themselves below the minimal level of physically fitness for participation or lacked motivation to travel 5 days/week are likely to have opted to not join the study. Furthermore, we lacked a control group to assess the differences in those who did not receive the intervention, although others have shown that physical inactivity over the short-term [30] or of similar duration to the current study [31] reported a worsening of insulin resistance and cardiometabolic health. In either case, this might be important for outcomes such as quality of life as we report improvements with lifestyle intervention.
In conclusion, current clinical guidelines for those with kidney disease recommend exercising 5 days/week for at least 30 min [32] . Our data highlights the feasibility of these recommendations for severely obese patients with CKD and suggest that these individuals can successfully perform this moderate to high intensity exercise prescription. Moreover, this type of exercise and diet intervention offers beneficial effects in terms of exercise capacity, insulin resistance and adipokines. However, whether these benefits and this type of lifestyle modification program is sustainable and leads to better kidney function and reduction in cardiovascular disease risk should be the focus of larger studies in the future.
